• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
Kassandra_Officer
Kassandra M. Officer
Associate
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4270
kassandra.officer@finnegan.com kassandra.officer@finnegan.com

Kassandra M. Officer

Associate

  • +1 202 408 4270 +1 202 408 4270
  • kassandra.officer@finnegan.com kassandra.officer@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard
Kassandra_Officer
Kassandra Officer focuses on patent and trade secret litigation before U.S. district courts as well as on post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). Her practice encompasses a range of technologies, with an emphasis on chemicals, pharmaceuticals, and medical devices.

Kassandra represents pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act as well as parties in trade secret misappropriation actions. Her experience covers numerous aspects of trial preparation, including conducting offensive and defensive discovery, taking and defending fact and expert depositions, managing day-to-day litigation activities, preparing for and going to trial, and drafting post-trial briefing. Kassandra has also counseled clients regarding quarantine and clean-room redesign procedures.

Kassandra represents clients in inter partes review (IPR) and other contested proceedings before the PTAB. Her experience includes developing validity positions, drafting written submissions, and preparing technical expert witnesses. Kassandra has an active patent prosecution and counseling practice, preparing and prosecuting U.S. patent applications on behalf of international clients, with a focus on chemical subject matter, including pharmaceutical and veterinary drug products.

While in law school, Kassandra worked as a legal extern for a medical device company, where she conducted patent portfolio analysis and mapped competitors' technologies in order to formulate patent strategies. In addition, Kassandra aided in developing the Maurer School of Law Intellectual Property Clinic, where she provided patent due diligence and patent drafting services for several clients.

Kassandra's pro bono experience includes assisting veterans with claims before the U.S. Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit.

Et Cetera

  • Received CALI Excellence for the Future Awards in Advanced Patent Law, 2013; Patent Prosecution, 2013; Federal Circuit Advocacy, 2014.

Experience

Lannett Holdings, Inc. v. AstraZeneca AB

Member of team that defended patent owner in two IPRs relating to Zomig® Nasal Spray, leading to non-institution decisions in both proceedings. 

IPR2015-01629, -01630, PTAB

AstraZeneca AB v. Aurobindo Pharma, Ltd.

Member of team that represented AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against multiple generic challengers on its Onlgyza® and Kombiglyze® XR pharmaceutical drug products. Patent sustained in district court. Patent sustained in district court and parallel inter partes review (IPR) proceeding.

1:14-cv-00664, D. Del., Judge Sleet
IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney

Coalition for Affordable Drugs V LLC v. Biogen

Member of team that defended client in three inter partes reviews (IPR) relating to Tecfidera®, leading to non-institution decisions in the first two proceedings and a final decision confirming patentability in the third proceeding.

IPR2015-01086, -01136, -01993, PTAB

Smith & Nephew v. ConforMIS, Inc.

Represented patent owner ConforMIS, Inc. in sixteen IPRs relating to patient-specific surgical tools, leading to non-institution decisions in several proceedings.

IPR2016-01874; IPR2017-00115, -00307, -00372, -00373, -00487, -00488, -00510, -00511, -00544, -00545, -00778, -00779, -00780, -00983, -00984, PTAB, Judges Bunting, Scanlon, Weiker, Worth

E. I. du Pont de Nemours v. Synvina C.V.

Represented DuPont and ADM in a successful Federal Circuit appeal from an IPR proceeding, resulting in reversal of the PTAB’s decision and invalidation of all challenged claims of Synvina’s patent directed to production of 2,5-furan dicarboxylic acid.

17-1977, Fed. Cir.

Insights

Articles

Improper Markush Grouping Improper Markush Grouping

June 2018

CIPA Journal

Articles

Client-Attorney Privilege in the U.S. Client-Attorney Privilege in the U.S.

December 1, 2017

CIPA Journal

Conference

American Chemical Society National Meeting American Chemical Society National Meeting

August 20-24, 2017

Washington

Workshop

American Chemical Society Middle Atlantic Regional Meeting American Chemical Society Middle Atlantic Regional Meeting

June 4-6, 2017

Hershey

Articles

Navigating the Emerging Procedural Boundaries in IPR Proceedings Navigating the Emerging Procedural Boundaries in IPR Proceedings

May/June 2017

IP Litigator

IP FDA Blog

FDA Amends Regulations Governing the Approval of ANDAs and 505(b)(2) Applications FDA Amends Regulations Governing the Approval of ANDAs and 505(b)(2) Applications

October 7, 2016

2 more

Professional Activities

  • American Chemical Society
  • American Bar Association
  • American Intellectual Property Law Association
Admissions and Education

Admissions

  • District of Columbia
  • Massachusetts
  • U.S. Patent and Trademark Office

Education

Indiana University Maurer School of Law
J.D., cum laude, 2014
The Ohio State University
B.S., Chemical & Biomolecular Engineering, magna cum laude, 2011

Kassandra's Practices

Copyright
Patent Litigation
Branded Hatch-Waxman (ANDA)
Patent Trial
Settlement
Patent Office Examinations
Prosecution
Patent Portfolio Management, Monetization, and Transactions
Due Diligence
Opinions and Counseling
Post-Grant Proceedings
Appeals of PTAB Trial Decisions
IPR, PGR, and CBM
Trade Secrets

Kassandra's Industries

Electronics and Information Technology
Electronic Devices and Components
Energy
Chemical
Clean Energy and Renewables
Oil and Gas
Life Sciences
Biologics
Medical Device and Diagnostics
Pharmaceutical
Transportation and Logistics
Automotive

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP